secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001493152-24-007772
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas reports positive MAT2203 compassionate use data: 12 of 15 patients improved, all completers resolved.
--------------------------------------------------------------------------------

- 19 patients enrolled in compassionate-use program for oral antifungal MAT2203; 15 evaluable.
- 12 of 15 patients had complete clinical resolution or objective improvement in infection markers.
- All 5 patients who completed full treatment (2 weeks to 1 year) had complete resolution with no relapse.
- All patients who transitioned from AmBisome due to renal toxicity saw return to baseline renal function.
- Patients treated at 9 major institutions including Johns Hopkins, NIH, Memorial Sloan Kettering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224007772/0001493152-24-007772-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315224007772/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007772

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer